Therefore, we highlight that lung‐cancer‐related STMs (NSE, CEA, CA125, CA153, CYFRA21‐1, SCC) could be potential predictors of resistance and prognosis of lung cancer treated with targeted therapy. This evidence concerns the gene MUC16 and lung carcinoma.